«Possibilities of a unified approach to the treatment of IgE-associated respiratory diseases. Clinical Experience exchange».

Inflammatory diseases of the upper and lower respiratory airways, such as allergic rhinitis, nasal polyposis, bronchial asthma have common proinflammatory mechanisms, mediated by IgE-dependent cascade of inflammation. Concurrent existence of asthma and allergic rhinitis and/or nasal polyposis increases clinical symptoms severity, disease course aggravation and eventually disease control loss for the patient. Anti-IgE-therapy is pathogenetically justified effective and safe therapeutic option for various patient groups. Today principles of interdisciplinary approach are in practice to target upper and lower respiratory diseases management, which determines the success of biological therapy. ENT, pulmonology and allergy specialists define patient management tactics in close collaboration taking into consideration diseases manifestation. The proven efficacy and safety of оmalizumab makes this drug a universal tool to achieve IgE-associated diseases control and an alternative solution for surgical intervention and therapy with systemic corticosteroids.